p38-MAPK inhibition and endotoxin induced tubular dysfunction in men

Journal of Endotoxin Research

Volumn 10, Issue 6, 2004, Pages 402-405

  Zijlstra, Jan G ^a   Tulleken, Jaap E ^a   Ligtenberg, Jack J M ^a   de Boer, Peter ^b   van der Werf, Tjip S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Endotoxin; p 38 MAPK inhibition; Renal failure; Tubulopathy

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; BETA 2 MICROGLOBULIN; ENDOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; EXPERIMENTAL MODEL; HUMAN; KIDNEY INJURY; MALE; NORMAL HUMAN; TUBULAR DYSFUNCTION; URINALYSIS; URINARY EXCRETION;

ADULT; BETA 2-MICROGLOBULIN; BETA-N-ACETYL-GALACTOSAMINIDASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; HUMANS; IMIDAZOLES; KIDNEY TUBULES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES;

ESCHERICHIA COLI;

EID: 10244279120     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805104225005869     Document Type: Article

References (14)

1. Wadsworth SA, Cavender DE, Beers SA et al. RWJ-67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999; 291: 680-687.
2. Fijen JW, Tulleken JE, Kobold AC et al. Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med 2002; 30: 841-845.
3. Fijen JW, Kobold AC, de Boer P et al. Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Intern Med 2000; 11: 89-95.
4. Fijen JW, Zijlstra JG, de Boer P et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001; 124: 16-20.
5. Faas MM, Moes H, Fijen JW et al. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol 2002; 127 337-343.
6. Iwami KI, Matsuguchi T, Masuda A et al. Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165: 6682-6686.
7. Hoekman K, Van Nieuwkoop JA, Willemze R. The significance of beta-2 microglobulin in clinical medicine. Neth J Med 1985; 28 551-557.
8. Price RG. Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications. Eur J Clin Chem Clin Biochem 1992; 30: 693-705.
9. Tassi C, Abbritti G, Mancuso F et al. Activity and isoenzyme profile of N-acetyl-beta-D-glucosaminidase in urine from workers exposed to cadmium. Clin Chim Acta 2000; 299: 55-64.
10. Khan RZ, Badr KF. Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 1999; 14: 814-818.
11. Thijs A, Thijs LG. Pathogenesis of renal failure in sepsis. Kidney Int Suppl 1998; 66: S34-S37.
12. Ueda N, Shah SV. Tubular cell damage in acute renal failure-apoptosis, necrosis, or both. Nephrol Dial Transplant 2000; 15: 318-323.
13. Knotek M, Rogachev B, Wang W et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001; 59: 2243-2249.
14. Cunningham PN, Dyanov HM, Park P et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168: 5817-5823.